Development
e-therapeutics plc
ETXPF
OTC PK
| 07/31/2023 | 04/30/2023 | 01/31/2023 | 10/31/2022 | 07/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 411.30K | 490.70K | 587.90K | 479.40K | 375.60K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 411.30K | 490.70K | 587.90K | 479.40K | 375.60K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 411.30K | 490.70K | 587.90K | 479.40K | 375.60K |
| SG&A Expenses | 4.33M | 4.24M | 4.28M | 4.87M | 5.55M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.79M | 14.24M | 13.09M | 13.63M | 14.41M |
| Operating Income | -15.38M | -13.75M | -12.50M | -13.15M | -14.04M |
| Income Before Tax | -14.44M | -13.01M | -11.95M | -12.85M | -13.98M |
| Income Tax Expenses | -2.22M | -2.00M | -1.83M | -1.88M | -1.96M |
| Earnings from Continuing Operations | -12.22 | -11.02 | -10.12 | -10.97 | -12.03 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.22M | -11.02M | -10.12M | -10.97M | -12.03M |
| EBIT | -15.38M | -13.75M | -12.50M | -13.15M | -14.04M |
| EBITDA | -14.96M | -13.36M | -12.12M | -12.78M | -13.73M |
| EPS Basic | -0.02 | -0.02 | -0.02 | -0.02 | -0.03 |
| Normalized Basic EPS | -0.02 | -0.01 | -0.01 | -0.02 | -0.02 |
| EPS Diluted | -0.02 | -0.02 | -0.02 | -0.02 | -0.03 |
| Normalized Diluted EPS | -0.02 | -0.01 | -0.01 | -0.02 | -0.02 |
| Average Basic Shares Outstanding | 2.27B | 2.21B | 2.15B | 2.05B | 1.95B |
| Average Diluted Shares Outstanding | 2.27B | 2.21B | 2.15B | 2.05B | 1.95B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |